Urology

Top Medical News
4 days ago
Levels of prostate-specific antigen (PSA) are higher in infertile men than in their fertile counterparts, a recent study has shown. Moreover, PSA >1 ng/mL is more common among infertile men younger than 40 years of age.
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
12 Jan 2021
The urine albumin-to-creatinine ratio (uACR) is an easy and reliable method of ruling out proteinuria >500 mg per day among patients with systemic light chain (AL) amyloidosis, performing relatively well against the 24-hour urine protein collection (24hUP) gold standard, a recent study has found.
10 Jan 2021
The proximal ureteral diameter is a significant predictor of high-grade ureteral injury during ureteral access sheath placement, with a smaller diameter increasing the risk and severity of such injury, according to a recent study.
10 Jan 2021
An overactive bladder, with (wet) or without urgency incontinence (dry), can significantly predict falls in older adults with a low absolute fall risk, suggests a study.
09 Jan 2021
In the treatment of patients with acute renal colic, paracetamol and parecoxib are equally effective at dulling pain, reducing the need for rescue analgesia with minimal adverse events, as shown in a study.
Stephen Padilla, 08 Jan 2021
Androgen deprivation therapy (ADT) in men with prostate cancer increases the risk of dementia and Alzheimer’s disease, reveals a recent study. Such risk further increases when said treatment is given for more than 12 months.
Special Reports
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
26 Nov 2019
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
15 Mar 2019
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Conference Reports
Audrey Abella, 18 Nov 2020
The investigational combination drug comprising the fourth-generation cephalosporin cefepime and the novel, potent extended-spectrum β-lactamase (ESBL) inhibitor enmetazobactam (FPE) demonstrated superiority to the piperacillin-tazobactam (PTZ) regimen in patients with complicated* urinary tract infection/acute pyelonephritis (cUTI/AP) caused by ESBL-producing Enterobacterales, according to the results of the ALLIUM trial.
Pearl Toh, 16 Nov 2020
The oral prodrug tebipenem pivoxil hydrobromide (TBP-PI-HBr) was as effective as intravenous ertapenem in clearing infection and achieving clinical cure in adult patients hospitalized with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP), shows a head-to-head comparison study, ADAPT-PO.
Audrey Abella, 11 Nov 2020
The SURE*-1 trial demonstrated the potential of a novel, broad-spectrum penem antibiotic – sulopenem etzadroxil/probenecid – for women with uncomplicated urinary tract infection (uUTI).
Audrey Abella, 23 Mar 2020
The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU 2020. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).
Elaine Soliven, 14 Mar 2020
The use of sipuleucel-T significantly prolongs overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), regardless of treatment setting, based on real-world data presented at ASCO GU 2020.
Pearl Toh, 09 Mar 2020
A combination therapy of enfortumab vedotin and pembrolizumab shows promising activity, with rapid and durable responses in the first-line setting for patients with metastatic urothelial carcinoma (mUC) ineligible to receive cisplatin, according to updates from the EV-103* study presented at GUCS 2020.
Roshini Claire Anthony, 05 Mar 2020

Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU 2020.